{"transactions":[{"id":858603,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":62572,"kind":"person","name":"Konidaris Tasos","position":1,"cik":"0001320982","reported_name":"Konidaris Tasos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President & CFO"}}],"security":"Restricted Stock Units","published_at":"2026-03-05T21:31:57.000Z","date":"2026-03-04","kind":"exercise","planned":false,"acquired":false,"shares":49982,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"On March 4, 2024, the reporting person was granted 175,926 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"On March 4, 2024, the reporting person was granted 175,926 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date."}],"balance_after":87963,"derivative":{"underlying":"Class A Common Stock","underlying_shares":49982},"source":{"system":"sec-edgar","filing":"0001628280-26-015239","document":"wk-form4_1772746314.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828026015239/wk-form4_1772746314.xml","form_type":"4"}},{"id":858602,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":62572,"kind":"person","name":"Konidaris Tasos","position":1,"cik":"0001320982","reported_name":"Konidaris Tasos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President & CFO"}}],"security":"Performance-Based Restricted Stock Units","published_at":"2026-03-05T21:31:57.000Z","date":"2026-03-03","kind":"exercise","planned":false,"acquired":false,"shares":458716,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.  On March 3, 2023, the Reporting Person was granted performance-based restricted stock units, scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period.  These units were certified as meeting the performance threshold that resulted in vesting of 200% of the targeted number of restricted stock units and these restricted stock units were deemed earned and vested on March 3, 2026 and settled into shares of Class A Common Stock on a one-for-one basis.  Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of these performance-based restricted stock unites.  The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations.  See footnote 5."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.  On March 3, 2023, the Reporting Person was granted performance-based restricted stock units, scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period.  These units were certified as meeting the performance threshold that resulted in vesting of 200% of the targeted number of restricted stock units and these restricted stock units were deemed earned and vested on March 3, 2026 and settled into shares of Class A Common Stock on a one-for-one basis.  Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of these performance-based restricted stock unites.  The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations.  See footnote 5."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.  On March 3, 2023, the Reporting Person was granted performance-based restricted stock units, scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period.  These units were certified as meeting the performance threshold that resulted in vesting of 200% of the targeted number of restricted stock units and these restricted stock units were deemed earned and vested on March 3, 2026 and settled into shares of Class A Common Stock on a one-for-one basis.  Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of these performance-based restricted stock unites.  The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations.  See footnote 5."}],"balance_after":0,"derivative":{"underlying":"Class A Common Stock","underlying_shares":458716},"source":{"system":"sec-edgar","filing":"0001628280-26-015239","document":"wk-form4_1772746314.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828026015239/wk-form4_1772746314.xml","form_type":"4"}},{"id":858601,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":62572,"kind":"person","name":"Konidaris Tasos","position":1,"cik":"0001320982","reported_name":"Konidaris Tasos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President & CFO"}}],"security":"Restricted Stock Units","published_at":"2026-03-05T21:31:57.000Z","date":"2026-03-03","kind":"exercise","planned":false,"acquired":false,"shares":28538,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"On March 3, 2025, the reporting person was granted 114,155 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"On March 3, 2025, the reporting person was granted 114,155 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date."}],"balance_after":85617,"derivative":{"underlying":"Class A Common Stock","underlying_shares":28538},"source":{"system":"sec-edgar","filing":"0001628280-26-015239","document":"wk-form4_1772746314.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828026015239/wk-form4_1772746314.xml","form_type":"4"}},{"id":858600,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":62572,"kind":"person","name":"Konidaris Tasos","position":1,"cik":"0001320982","reported_name":"Konidaris Tasos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President & CFO"}}],"security":"Restricted Stock Units","published_at":"2026-03-05T21:31:57.000Z","date":"2026-03-03","kind":"exercise","planned":false,"acquired":false,"shares":57339,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"On March 3, 2023, the reporting person was granted 229,358 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"On March 3, 2023, the reporting person was granted 229,358 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date."}],"balance_after":57340,"derivative":{"underlying":"Class A Common Stock","underlying_shares":57339},"source":{"system":"sec-edgar","filing":"0001628280-26-015239","document":"wk-form4_1772746314.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828026015239/wk-form4_1772746314.xml","form_type":"4"}},{"id":858599,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":62572,"kind":"person","name":"Konidaris Tasos","position":1,"cik":"0001320982","reported_name":"Konidaris Tasos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President & CFO"}}],"security":"Restricted Stock Units","published_at":"2026-03-05T21:31:57.000Z","date":"2026-03-03","kind":"exercise","planned":false,"acquired":false,"shares":45290,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"On March 3, 2022, the reporting person was granted 181,159 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"On March 3, 2022, the reporting person was granted 181,159 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date."}],"balance_after":0,"derivative":{"underlying":"Class A Common Stock","underlying_shares":45290},"source":{"system":"sec-edgar","filing":"0001628280-26-015239","document":"wk-form4_1772746314.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828026015239/wk-form4_1772746314.xml","form_type":"4"}},{"id":858598,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":62572,"kind":"person","name":"Konidaris Tasos","position":1,"cik":"0001320982","reported_name":"Konidaris Tasos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President & CFO"}}],"security":"Class A Common Stock","published_at":"2026-03-05T21:31:57.000Z","date":"2026-03-04","kind":"tax_withholding","planned":false,"acquired":false,"shares":22035,"price":13.3,"value":293065.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units."}],"balance_after":449434,"source":{"system":"sec-edgar","filing":"0001628280-26-015239","document":"wk-form4_1772746314.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828026015239/wk-form4_1772746314.xml","form_type":"4"}},{"id":858597,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":62572,"kind":"person","name":"Konidaris Tasos","position":1,"cik":"0001320982","reported_name":"Konidaris Tasos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President & CFO"}}],"security":"Class A Common Stock","published_at":"2026-03-05T21:31:57.000Z","date":"2026-03-04","kind":"exercise","planned":false,"acquired":true,"shares":43982,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock."}],"balance_after":471469,"source":{"system":"sec-edgar","filing":"0001628280-26-015239","document":"wk-form4_1772746314.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828026015239/wk-form4_1772746314.xml","form_type":"4"}},{"id":858596,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":62572,"kind":"person","name":"Konidaris Tasos","position":1,"cik":"0001320982","reported_name":"Konidaris Tasos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President & CFO"}}],"security":"Class A Common Stock","published_at":"2026-03-05T21:31:57.000Z","date":"2026-03-03","kind":"tax_withholding","planned":false,"acquired":false,"shares":229817,"price":13.31,"value":3058864.27,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of performance-based restricted stock units."}],"balance_after":427487,"source":{"system":"sec-edgar","filing":"0001628280-26-015239","document":"wk-form4_1772746314.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828026015239/wk-form4_1772746314.xml","form_type":"4"}},{"id":858595,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":62572,"kind":"person","name":"Konidaris Tasos","position":1,"cik":"0001320982","reported_name":"Konidaris Tasos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President & CFO"}}],"security":"Class A Common Stock","published_at":"2026-03-05T21:31:57.000Z","date":"2026-03-03","kind":"exercise","planned":false,"acquired":true,"shares":458716,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.  On March 3, 2023, the Reporting Person was granted performance-based restricted stock units, scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period.  These units were certified as meeting the performance threshold that resulted in vesting of 200% of the targeted number of restricted stock units and these restricted stock units were deemed earned and vested on March 3, 2026 and settled into shares of Class A Common Stock on a one-for-one basis.  Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of these performance-based restricted stock unites.  The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations.  See footnote 5."}],"balance_after":657304,"source":{"system":"sec-edgar","filing":"0001628280-26-015239","document":"wk-form4_1772746314.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828026015239/wk-form4_1772746314.xml","form_type":"4"}},{"id":858594,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":62572,"kind":"person","name":"Konidaris Tasos","position":1,"cik":"0001320982","reported_name":"Konidaris Tasos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President & CFO"}}],"security":"Class A Common Stock","published_at":"2026-03-05T21:31:57.000Z","date":"2026-03-03","kind":"tax_withholding","planned":false,"acquired":false,"shares":14298,"price":13.31,"value":190306.38,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units."}],"balance_after":198588,"source":{"system":"sec-edgar","filing":"0001628280-26-015239","document":"wk-form4_1772746314.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828026015239/wk-form4_1772746314.xml","form_type":"4"}},{"id":858593,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":62572,"kind":"person","name":"Konidaris Tasos","position":1,"cik":"0001320982","reported_name":"Konidaris Tasos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President & CFO"}}],"security":"Class A Common Stock","published_at":"2026-03-05T21:31:57.000Z","date":"2026-03-03","kind":"exercise","planned":false,"acquired":true,"shares":28538,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock."}],"balance_after":212886,"source":{"system":"sec-edgar","filing":"0001628280-26-015239","document":"wk-form4_1772746314.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828026015239/wk-form4_1772746314.xml","form_type":"4"}},{"id":858592,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":62572,"kind":"person","name":"Konidaris Tasos","position":1,"cik":"0001320982","reported_name":"Konidaris Tasos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President & CFO"}}],"security":"Class A Common Stock","published_at":"2026-03-05T21:31:57.000Z","date":"2026-03-03","kind":"tax_withholding","planned":false,"acquired":false,"shares":24251,"price":13.31,"value":322780.81,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units."}],"balance_after":184348,"source":{"system":"sec-edgar","filing":"0001628280-26-015239","document":"wk-form4_1772746314.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828026015239/wk-form4_1772746314.xml","form_type":"4"}},{"id":858591,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":62572,"kind":"person","name":"Konidaris Tasos","position":1,"cik":"0001320982","reported_name":"Konidaris Tasos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President & CFO"}}],"security":"Class A Common Stock","published_at":"2026-03-05T21:31:57.000Z","date":"2026-03-03","kind":"exercise","planned":false,"acquired":true,"shares":57339,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock."}],"balance_after":208599,"source":{"system":"sec-edgar","filing":"0001628280-26-015239","document":"wk-form4_1772746314.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828026015239/wk-form4_1772746314.xml","form_type":"4"}},{"id":858590,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":62572,"kind":"person","name":"Konidaris Tasos","position":1,"cik":"0001320982","reported_name":"Konidaris Tasos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President & CFO"}}],"security":"Class A Common Stock","published_at":"2026-03-05T21:31:57.000Z","date":"2026-03-03","kind":"tax_withholding","planned":false,"acquired":false,"shares":16182,"price":13.31,"value":215382.42,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units."}],"balance_after":151260,"source":{"system":"sec-edgar","filing":"0001628280-26-015239","document":"wk-form4_1772746314.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828026015239/wk-form4_1772746314.xml","form_type":"4"}},{"id":858589,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":62572,"kind":"person","name":"Konidaris Tasos","position":1,"cik":"0001320982","reported_name":"Konidaris Tasos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President & CFO"}}],"security":"Class A Common Stock","published_at":"2026-03-05T21:31:57.000Z","date":"2026-03-03","kind":"exercise","planned":false,"acquired":true,"shares":45290,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock."}],"balance_after":167442,"source":{"system":"sec-edgar","filing":"0001628280-26-015239","document":"wk-form4_1772746314.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828026015239/wk-form4_1772746314.xml","form_type":"4"}},{"id":867535,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":62572,"kind":"person","name":"Konidaris Tasos","position":1,"cik":"0001320982","reported_name":"Konidaris Tasos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President & CFO"}}],"security":"Performance-Based Restricted Stock Units","published_at":"2026-03-03T21:28:01.000Z","date":"2026-03-02","kind":"grant","planned":false,"acquired":true,"shares":72622,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Represents a performance-based restricted stock unit grant of 72,622 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2029, the last day of the performance period."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Represents a performance-based restricted stock unit grant of 72,622 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2029, the last day of the performance period."}],"balance_after":72622,"derivative":{"underlying":"Class A Common Stock","underlying_shares":72622},"source":{"system":"sec-edgar","filing":"0001628280-26-013887","document":"wk-form4_1772573278.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828026013887/wk-form4_1772573278.xml","form_type":"4"}},{"id":867534,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":62572,"kind":"person","name":"Konidaris Tasos","position":1,"cik":"0001320982","reported_name":"Konidaris Tasos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President & CFO"}}],"security":"Restricted Stock Units","published_at":"2026-03-03T21:28:01.000Z","date":"2026-03-02","kind":"grant","planned":false,"acquired":true,"shares":72622,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units vest in four equal annual installments beginning on March 2, 2027."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units vest in four equal annual installments beginning on March 2, 2027."}],"balance_after":72622,"derivative":{"underlying":"Class A Common Stock","underlying_shares":72622},"source":{"system":"sec-edgar","filing":"0001628280-26-013887","document":"wk-form4_1772573278.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828026013887/wk-form4_1772573278.xml","form_type":"4"}},{"id":1065377,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":62572,"kind":"person","name":"Konidaris Tasos","position":1,"cik":"0001320982","reported_name":"Konidaris Tasos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President & CFO"}}],"security":"Class A Common Stock","published_at":"2025-08-15T20:30:19.000Z","date":"2025-08-15","kind":"sale","planned":false,"acquired":false,"shares":219159,"price":9.43,"value":2066669.37,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price included in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.40 to $9.47 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnote."}],"balance_after":122152,"source":{"system":"sec-edgar","filing":"0001723128-25-000051","document":"wk-form4_1755289808.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000172312825000051/wk-form4_1755289808.xml","form_type":"4"}},{"id":1065376,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":62572,"kind":"person","name":"Konidaris Tasos","position":1,"cik":"0001320982","reported_name":"Konidaris Tasos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President & CFO"}}],"security":"Class A Common Stock","published_at":"2025-08-15T20:30:19.000Z","date":"2025-08-14","kind":"sale","planned":false,"acquired":false,"shares":119206,"price":9.3,"value":1108615.8,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price included in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.25 to $9.34 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnote."}],"balance_after":341311,"source":{"system":"sec-edgar","filing":"0001723128-25-000051","document":"wk-form4_1755289808.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000172312825000051/wk-form4_1755289808.xml","form_type":"4"}},{"id":1065375,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":62572,"kind":"person","name":"Konidaris Tasos","position":1,"cik":"0001320982","reported_name":"Konidaris Tasos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President & CFO"}}],"security":"Class A Common Stock","published_at":"2025-08-15T20:30:19.000Z","date":"2025-08-13","kind":"sale","planned":false,"acquired":false,"shares":161365,"price":9.22,"value":1487785.3,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price included in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.12 to $9.40 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnote."}],"balance_after":460517,"source":{"system":"sec-edgar","filing":"0001723128-25-000051","document":"wk-form4_1755289808.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000172312825000051/wk-form4_1755289808.xml","form_type":"4"}},{"id":1217478,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":62572,"kind":"person","name":"Konidaris Tasos","position":1,"cik":"0001320982","reported_name":"Konidaris Tasos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President & CFO"}}],"security":"Class A Common Stock","published_at":"2025-03-07T21:17:16.000Z","date":"2025-03-05","kind":"sale","planned":false,"acquired":false,"shares":100000,"price":8.91,"value":891000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price included in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.84 to $8.98 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnote."}],"balance_after":621882,"source":{"system":"sec-edgar","filing":"0001628280-25-011303","document":"wk-form4_1741382230.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828025011303/wk-form4_1741382230.xml","form_type":"4"}},{"id":1222592,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":62572,"kind":"person","name":"Konidaris Tasos","position":1,"cik":"0001320982","reported_name":"Konidaris Tasos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President & CFO"}}],"security":"Restricted Stock Units","published_at":"2025-03-06T00:53:26.000Z","date":"2025-03-04","kind":"exercise","planned":false,"acquired":false,"shares":43981,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"On March 4, 2024, the Reporting Person was granted 175,926 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F11","text":"On March 4, 2024, the Reporting Person was granted 175,926 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date."}],"balance_after":131945,"derivative":{"underlying":"Class A Common Stock","underlying_shares":43981},"source":{"system":"sec-edgar","filing":"0001628280-25-010713","document":"wk-form4_1741222400.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828025010713/wk-form4_1741222400.xml","form_type":"4"}},{"id":1222591,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":62572,"kind":"person","name":"Konidaris Tasos","position":1,"cik":"0001320982","reported_name":"Konidaris Tasos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President & CFO"}}],"security":"Restricted Stock Units","published_at":"2025-03-06T00:53:26.000Z","date":"2025-03-03","kind":"grant","planned":false,"acquired":true,"shares":114155,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"The restricted stock units vest in four equal annual installments beginning on March 3, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F10","text":"The restricted stock units vest in four equal annual installments beginning on March 3, 2026."}],"balance_after":114154,"derivative":{"underlying":"Class A Common Stock","underlying_shares":114155},"source":{"system":"sec-edgar","filing":"0001628280-25-010713","document":"wk-form4_1741222400.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828025010713/wk-form4_1741222400.xml","form_type":"4"}},{"id":1222590,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":62572,"kind":"person","name":"Konidaris Tasos","position":1,"cik":"0001320982","reported_name":"Konidaris Tasos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President & CFO"}}],"security":"Performance-Based Restricted Stock Units","published_at":"2025-03-06T00:53:26.000Z","date":"2025-03-03","kind":"grant","planned":false,"acquired":true,"shares":228310,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F8","text":"Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"Represents a performance-based restricted stock unit grant of 114,155 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock\nachieving certain average closing prices per share over a three-year performance period. The number of performance-based restricted stock units reported represents the maximum number of shares\nissuable under the award. The number that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in\nthe table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2028, the last day of the performance\nperiod."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"Represents a performance-based restricted stock unit grant of 114,155 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock\nachieving certain average closing prices per share over a three-year performance period. The number of performance-based restricted stock units reported represents the maximum number of shares\nissuable under the award. The number that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in\nthe table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2028, the last day of the performance\nperiod."}],"balance_after":228310,"derivative":{"underlying":"Class A Common Stock","underlying_shares":228310},"source":{"system":"sec-edgar","filing":"0001628280-25-010713","document":"wk-form4_1741222400.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828025010713/wk-form4_1741222400.xml","form_type":"4"}},{"id":1222589,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":62572,"kind":"person","name":"Konidaris Tasos","position":1,"cik":"0001320982","reported_name":"Konidaris Tasos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President & CFO"}}],"security":"Performance-Based Restricted Stock Units","published_at":"2025-03-06T00:53:26.000Z","date":"2025-03-03","kind":"exercise","planned":false,"acquired":false,"shares":181159,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. On March 3, 2022, the Reporting Person was granted\nperformance-based restricted stock units, scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. These\nunits were certified as meeting the performance threshold that resulted in vesting of 100% of the targeted number of restricted stock units and these restricted stock units were deemed earned and vested on March 3, 2025 and settled into shares of Class A Common Stock on a one-for-one basis. Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of these performance-based restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 5."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. On March 3, 2022, the Reporting Person was granted\nperformance-based restricted stock units, scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. These\nunits were certified as meeting the performance threshold that resulted in vesting of 100% of the targeted number of restricted stock units and these restricted stock units were deemed earned and vested on March 3, 2025 and settled into shares of Class A Common Stock on a one-for-one basis. Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of these performance-based restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 5."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. On March 3, 2022, the Reporting Person was granted\nperformance-based restricted stock units, scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. These\nunits were certified as meeting the performance threshold that resulted in vesting of 100% of the targeted number of restricted stock units and these restricted stock units were deemed earned and vested on March 3, 2025 and settled into shares of Class A Common Stock on a one-for-one basis. Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of these performance-based restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 5."}],"balance_after":0,"derivative":{"underlying":"Class A Common Stock","underlying_shares":181159},"source":{"system":"sec-edgar","filing":"0001628280-25-010713","document":"wk-form4_1741222400.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828025010713/wk-form4_1741222400.xml","form_type":"4"}},{"id":1222588,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":62572,"kind":"person","name":"Konidaris Tasos","position":1,"cik":"0001320982","reported_name":"Konidaris Tasos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President & CFO"}}],"security":"Restricted Stock Units","published_at":"2025-03-06T00:53:26.000Z","date":"2025-03-03","kind":"exercise","planned":false,"acquired":false,"shares":57340,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"On March 3, 2023, the reporting person was granted 229,358 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"On March 3, 2023, the reporting person was granted 229,358 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date."}],"balance_after":114679,"derivative":{"underlying":"Class A Common Stock","underlying_shares":57340},"source":{"system":"sec-edgar","filing":"0001628280-25-010713","document":"wk-form4_1741222400.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828025010713/wk-form4_1741222400.xml","form_type":"4"}},{"id":1222587,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":62572,"kind":"person","name":"Konidaris Tasos","position":1,"cik":"0001320982","reported_name":"Konidaris Tasos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President & CFO"}}],"security":"Restricted Stock Units","published_at":"2025-03-06T00:53:26.000Z","date":"2025-03-03","kind":"exercise","planned":false,"acquired":false,"shares":45290,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"On March 3, 2022, the reporting person was granted 181,159 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"On March 3, 2022, the reporting person was granted 181,159 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date."}],"balance_after":45290,"derivative":{"underlying":"Class A Common Stock","underlying_shares":45290},"source":{"system":"sec-edgar","filing":"0001628280-25-010713","document":"wk-form4_1741222400.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828025010713/wk-form4_1741222400.xml","form_type":"4"}},{"id":1222586,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":62572,"kind":"person","name":"Konidaris Tasos","position":1,"cik":"0001320982","reported_name":"Konidaris Tasos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President & CFO"}}],"security":"Class A Common Stock","published_at":"2025-03-06T00:53:26.000Z","date":"2025-03-04","kind":"tax_withholding","planned":false,"acquired":false,"shares":22497,"price":8.84,"value":198873.48,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units."}],"balance_after":721882,"source":{"system":"sec-edgar","filing":"0001628280-25-010713","document":"wk-form4_1741222400.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828025010713/wk-form4_1741222400.xml","form_type":"4"}},{"id":1222585,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":62572,"kind":"person","name":"Konidaris Tasos","position":1,"cik":"0001320982","reported_name":"Konidaris Tasos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President & CFO"}}],"security":"Class A Common Stock","published_at":"2025-03-06T00:53:26.000Z","date":"2025-03-04","kind":"exercise","planned":false,"acquired":true,"shares":43981,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock."}],"balance_after":744379,"source":{"system":"sec-edgar","filing":"0001628280-25-010713","document":"wk-form4_1741222400.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828025010713/wk-form4_1741222400.xml","form_type":"4"}},{"id":1222584,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":62572,"kind":"person","name":"Konidaris Tasos","position":1,"cik":"0001320982","reported_name":"Konidaris Tasos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President & CFO"}}],"security":"Class A Common Stock","published_at":"2025-03-06T00:53:26.000Z","date":"2025-03-03","kind":"tax_withholding","planned":false,"acquired":false,"shares":92663,"price":8.76,"value":811727.88,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of performance-based restricted stock units."}],"balance_after":700398,"source":{"system":"sec-edgar","filing":"0001628280-25-010713","document":"wk-form4_1741222400.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828025010713/wk-form4_1741222400.xml","form_type":"4"}},{"id":1222583,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":62572,"kind":"person","name":"Konidaris Tasos","position":1,"cik":"0001320982","reported_name":"Konidaris Tasos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President & CFO"}}],"security":"Class A Common Stock","published_at":"2025-03-06T00:53:26.000Z","date":"2025-03-03","kind":"exercise","planned":false,"acquired":true,"shares":181159,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. On March 3, 2022, the Reporting Person was granted\nperformance-based restricted stock units, scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. These\nunits were certified as meeting the performance threshold that resulted in vesting of 100% of the targeted number of restricted stock units and these restricted stock units were deemed earned and vested on March 3, 2025 and settled into shares of Class A Common Stock on a one-for-one basis. Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of these performance-based restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 5."}],"balance_after":793061,"source":{"system":"sec-edgar","filing":"0001628280-25-010713","document":"wk-form4_1741222400.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828025010713/wk-form4_1741222400.xml","form_type":"4"}},{"id":1222582,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":62572,"kind":"person","name":"Konidaris Tasos","position":1,"cik":"0001320982","reported_name":"Konidaris Tasos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President & CFO"}}],"security":"Class A Common Stock","published_at":"2025-03-06T00:53:26.000Z","date":"2025-03-03","kind":"tax_withholding","planned":false,"acquired":false,"shares":24374,"price":8.76,"value":213516.24,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units."}],"balance_after":611902,"source":{"system":"sec-edgar","filing":"0001628280-25-010713","document":"wk-form4_1741222400.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828025010713/wk-form4_1741222400.xml","form_type":"4"}},{"id":1222581,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":62572,"kind":"person","name":"Konidaris Tasos","position":1,"cik":"0001320982","reported_name":"Konidaris Tasos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President & CFO"}}],"security":"Class A Common Stock","published_at":"2025-03-06T00:53:26.000Z","date":"2025-03-03","kind":"exercise","planned":false,"acquired":true,"shares":57340,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock."}],"balance_after":636276,"source":{"system":"sec-edgar","filing":"0001628280-25-010713","document":"wk-form4_1741222400.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828025010713/wk-form4_1741222400.xml","form_type":"4"}},{"id":1222580,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":62572,"kind":"person","name":"Konidaris Tasos","position":1,"cik":"0001320982","reported_name":"Konidaris Tasos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President & CFO"}}],"security":"Class A Common Stock","published_at":"2025-03-06T00:53:26.000Z","date":"2025-03-03","kind":"tax_withholding","planned":false,"acquired":false,"shares":16373,"price":8.76,"value":143427.48,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units."}],"balance_after":578936,"source":{"system":"sec-edgar","filing":"0001628280-25-010713","document":"wk-form4_1741222400.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828025010713/wk-form4_1741222400.xml","form_type":"4"}},{"id":1222579,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":62572,"kind":"person","name":"Konidaris Tasos","position":1,"cik":"0001320982","reported_name":"Konidaris Tasos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President & CFO"}}],"security":"Class A Common Stock","published_at":"2025-03-06T00:53:26.000Z","date":"2025-03-03","kind":"exercise","planned":false,"acquired":true,"shares":45290,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock."}],"balance_after":595309,"source":{"system":"sec-edgar","filing":"0001628280-25-010713","document":"wk-form4_1741222400.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828025010713/wk-form4_1741222400.xml","form_type":"4"}},{"id":1228780,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":62572,"kind":"person","name":"Konidaris Tasos","position":1,"cik":"0001320982","reported_name":"Konidaris Tasos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President & CFO"}}],"security":"Restricted Stock Units","published_at":"2025-03-04T23:59:24.000Z","date":"2025-03-01","kind":"exercise","planned":false,"acquired":false,"shares":36197,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On March 1, 2021, the reporting person was granted 144,788 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On March 1, 2021, the reporting person was granted 144,788 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date."}],"balance_after":0,"derivative":{"underlying":"Class A Common Stock","underlying_shares":36197},"source":{"system":"sec-edgar","filing":"0001628280-25-010115","document":"wk-form4_1741132756.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828025010115/wk-form4_1741132756.xml","form_type":"4"}},{"id":1228779,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":62572,"kind":"person","name":"Konidaris Tasos","position":1,"cik":"0001320982","reported_name":"Konidaris Tasos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President & CFO"}}],"security":"Class A Common Stock","published_at":"2025-03-04T23:59:24.000Z","date":"2025-03-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":13494,"price":8.67,"value":116992.98,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units."}],"balance_after":550019,"source":{"system":"sec-edgar","filing":"0001628280-25-010115","document":"wk-form4_1741132756.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828025010115/wk-form4_1741132756.xml","form_type":"4"}},{"id":1228778,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":62572,"kind":"person","name":"Konidaris Tasos","position":1,"cik":"0001320982","reported_name":"Konidaris Tasos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President & CFO"}}],"security":"Class A Common Stock","published_at":"2025-03-04T23:59:24.000Z","date":"2025-03-01","kind":"exercise","planned":false,"acquired":true,"shares":36197,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock."}],"balance_after":563513,"source":{"system":"sec-edgar","filing":"0001628280-25-010115","document":"wk-form4_1741132756.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828025010115/wk-form4_1741132756.xml","form_type":"4"}},{"id":1576767,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":62572,"kind":"person","name":"Konidaris Tasos","position":1,"cik":"0001320982","reported_name":"Konidaris Tasos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President & CFO"}}],"security":"Restricted Stock Units","published_at":"2024-03-14T20:17:56.000Z","date":"2024-03-12","kind":"exercise","planned":false,"acquired":false,"shares":87720,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On March 12, 2020, the reporting person was granted 350,877 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On March 12, 2020, the reporting person was granted 350,877 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date."}],"balance_after":0,"derivative":{"underlying":"Class A Common Stock","underlying_shares":87720},"source":{"system":"sec-edgar","filing":"0001628280-24-011223","document":"wk-form4_1710447463.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828024011223/wk-form4_1710447463.xml","form_type":"4"}},{"id":1576766,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":62572,"kind":"person","name":"Konidaris Tasos","position":1,"cik":"0001320982","reported_name":"Konidaris Tasos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President & CFO"}}],"security":"Class A Common Stock","published_at":"2024-03-14T20:17:56.000Z","date":"2024-03-12","kind":"tax_withholding","planned":false,"acquired":false,"shares":30790,"price":5.31,"value":163494.9,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units."}],"balance_after":527316,"source":{"system":"sec-edgar","filing":"0001628280-24-011223","document":"wk-form4_1710447463.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828024011223/wk-form4_1710447463.xml","form_type":"4"}},{"id":1576765,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":62572,"kind":"person","name":"Konidaris Tasos","position":1,"cik":"0001320982","reported_name":"Konidaris Tasos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President & CFO"}}],"security":"Class A Common Stock","published_at":"2024-03-14T20:17:56.000Z","date":"2024-03-12","kind":"exercise","planned":false,"acquired":true,"shares":87720,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock."}],"balance_after":558106,"source":{"system":"sec-edgar","filing":"0001628280-24-011223","document":"wk-form4_1710447463.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828024011223/wk-form4_1710447463.xml","form_type":"4"}},{"id":1596656,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":62572,"kind":"person","name":"Konidaris Tasos","position":1,"cik":"0001320982","reported_name":"Konidaris Tasos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President & CFO"}}],"security":"Performance-Based Restricted Stock Units","published_at":"2024-03-05T21:56:29.000Z","date":"2024-03-04","kind":"grant","planned":false,"acquired":true,"shares":351852,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F8","text":"Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"Represents a performance-based restricted stock unit grant of 175,926 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2027, the last day of the performance period."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"Represents a performance-based restricted stock unit grant of 175,926 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2027, the last day of the performance period."}],"balance_after":351852,"derivative":{"underlying":"Class A Common Stock","underlying_shares":351852},"source":{"system":"sec-edgar","filing":"0001628280-24-008979","document":"wk-form4_1709675759.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828024008979/wk-form4_1709675759.xml","form_type":"4"}},{"id":1596655,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":62572,"kind":"person","name":"Konidaris Tasos","position":1,"cik":"0001320982","reported_name":"Konidaris Tasos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President & CFO"}}],"security":"Restricted Stock Units","published_at":"2024-03-05T21:56:29.000Z","date":"2024-03-04","kind":"grant","planned":false,"acquired":true,"shares":175926,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The restricted stock units vest in four equal annual installments beginning on March 4, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The restricted stock units vest in four equal annual installments beginning on March 4, 2025."}],"balance_after":175926,"derivative":{"underlying":"Class A Common Stock","underlying_shares":175926},"source":{"system":"sec-edgar","filing":"0001628280-24-008979","document":"wk-form4_1709675759.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828024008979/wk-form4_1709675759.xml","form_type":"4"}},{"id":1596654,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":62572,"kind":"person","name":"Konidaris Tasos","position":1,"cik":"0001320982","reported_name":"Konidaris Tasos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President & CFO"}}],"security":"Restricted Stock Units","published_at":"2024-03-05T21:56:29.000Z","date":"2024-03-03","kind":"exercise","planned":false,"acquired":false,"shares":57339,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"On March 3, 2023, the reporting person was granted 229,358 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"On March 3, 2023, the reporting person was granted 229,358 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date."}],"balance_after":172019,"derivative":{"underlying":"Class A Common Stock","underlying_shares":57339},"source":{"system":"sec-edgar","filing":"0001628280-24-008979","document":"wk-form4_1709675759.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828024008979/wk-form4_1709675759.xml","form_type":"4"}},{"id":1596653,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":62572,"kind":"person","name":"Konidaris Tasos","position":1,"cik":"0001320982","reported_name":"Konidaris Tasos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President & CFO"}}],"security":"Restricted Stock Units","published_at":"2024-03-05T21:56:29.000Z","date":"2024-03-03","kind":"exercise","planned":false,"acquired":false,"shares":45290,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"On March 3, 2022, the reporting person was granted 181,159 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"On March 3, 2022, the reporting person was granted 181,159 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date."}],"balance_after":90580,"derivative":{"underlying":"Class A Common Stock","underlying_shares":45290},"source":{"system":"sec-edgar","filing":"0001628280-24-008979","document":"wk-form4_1709675759.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828024008979/wk-form4_1709675759.xml","form_type":"4"}},{"id":1596652,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":62572,"kind":"person","name":"Konidaris Tasos","position":1,"cik":"0001320982","reported_name":"Konidaris Tasos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President & CFO"}}],"security":"Restricted Stock Units","published_at":"2024-03-05T21:56:29.000Z","date":"2024-03-01","kind":"exercise","planned":false,"acquired":false,"shares":36197,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On March 1, 2021, the reporting person was granted 144,788 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On March 1, 2021, the reporting person was granted 144,788 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date."}],"balance_after":36197,"derivative":{"underlying":"Class A Common Stock","underlying_shares":36197},"source":{"system":"sec-edgar","filing":"0001628280-24-008979","document":"wk-form4_1709675759.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828024008979/wk-form4_1709675759.xml","form_type":"4"}},{"id":1596651,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":62572,"kind":"person","name":"Konidaris Tasos","position":1,"cik":"0001320982","reported_name":"Konidaris Tasos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President & CFO"}}],"security":"Class A Common Stock","published_at":"2024-03-05T21:56:29.000Z","date":"2024-03-03","kind":"tax_withholding","planned":false,"acquired":false,"shares":20126,"price":5.47,"value":110089.22,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units."}],"balance_after":470386,"source":{"system":"sec-edgar","filing":"0001628280-24-008979","document":"wk-form4_1709675759.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828024008979/wk-form4_1709675759.xml","form_type":"4"}},{"id":1596650,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":62572,"kind":"person","name":"Konidaris Tasos","position":1,"cik":"0001320982","reported_name":"Konidaris Tasos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President & CFO"}}],"security":"Class A Common Stock","published_at":"2024-03-05T21:56:29.000Z","date":"2024-03-03","kind":"exercise","planned":false,"acquired":true,"shares":57339,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock."}],"balance_after":490512,"source":{"system":"sec-edgar","filing":"0001628280-24-008979","document":"wk-form4_1709675759.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828024008979/wk-form4_1709675759.xml","form_type":"4"}},{"id":1596649,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":62572,"kind":"person","name":"Konidaris Tasos","position":1,"cik":"0001320982","reported_name":"Konidaris Tasos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President & CFO"}}],"security":"Class A Common Stock","published_at":"2024-03-05T21:56:29.000Z","date":"2024-03-03","kind":"tax_withholding","planned":false,"acquired":false,"shares":15897,"price":5.47,"value":86956.59,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units."}],"balance_after":433173,"source":{"system":"sec-edgar","filing":"0001628280-24-008979","document":"wk-form4_1709675759.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828024008979/wk-form4_1709675759.xml","form_type":"4"}},{"id":1596648,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":62572,"kind":"person","name":"Konidaris Tasos","position":1,"cik":"0001320982","reported_name":"Konidaris Tasos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President & CFO"}}],"security":"Class A Common Stock","published_at":"2024-03-05T21:56:29.000Z","date":"2024-03-03","kind":"exercise","planned":false,"acquired":true,"shares":45290,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock."}],"balance_after":449070,"source":{"system":"sec-edgar","filing":"0001628280-24-008979","document":"wk-form4_1709675759.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828024008979/wk-form4_1709675759.xml","form_type":"4"}},{"id":1596647,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":62572,"kind":"person","name":"Konidaris Tasos","position":1,"cik":"0001320982","reported_name":"Konidaris Tasos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President & CFO"}}],"security":"Class A Common Stock","published_at":"2024-03-05T21:56:29.000Z","date":"2024-03-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":13257,"price":5.47,"value":72515.79,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units."}],"balance_after":403780,"source":{"system":"sec-edgar","filing":"0001628280-24-008979","document":"wk-form4_1709675759.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828024008979/wk-form4_1709675759.xml","form_type":"4"}},{"id":1596646,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":62572,"kind":"person","name":"Konidaris Tasos","position":1,"cik":"0001320982","reported_name":"Konidaris Tasos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President & CFO"}}],"security":"Class A Common Stock","published_at":"2024-03-05T21:56:29.000Z","date":"2024-03-01","kind":"exercise","planned":false,"acquired":true,"shares":36197,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock."}],"balance_after":417037,"source":{"system":"sec-edgar","filing":"0001628280-24-008979","document":"wk-form4_1709675759.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828024008979/wk-form4_1709675759.xml","form_type":"4"}},{"id":1954298,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":62572,"kind":"person","name":"Konidaris Tasos","position":1,"cik":"0001320982","reported_name":"Konidaris Tasos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President & CFO"}}],"security":"Restricted Stock Units","published_at":"2023-03-14T20:30:10.000Z","date":"2023-03-12","kind":"exercise","acquired":false,"shares":87719,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On March 12, 2020, the reporting person was granted 350,877 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On March 12, 2020, the reporting person was granted 350,877 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date."}],"balance_after":87720,"derivative":{"underlying":"Class A Common Stock","underlying_shares":87719},"source":{"system":"sec-edgar","filing":"0001209191-23-018472","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000120919123018472/doc4.xml","form_type":"4"}},{"id":1954297,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":62572,"kind":"person","name":"Konidaris Tasos","position":1,"cik":"0001320982","reported_name":"Konidaris Tasos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President & CFO"}}],"security":"Class A Common Stock","published_at":"2023-03-14T20:30:10.000Z","date":"2023-03-12","kind":"exercise","acquired":true,"shares":87719,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of the Issuer's Class A Common Stock awarded to the reporting person in connection with the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock."}],"balance_after":380840,"source":{"system":"sec-edgar","filing":"0001209191-23-018472","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000120919123018472/doc4.xml","form_type":"4"}},{"id":1966089,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":62572,"kind":"person","name":"Konidaris Tasos","position":1,"cik":"0001320982","reported_name":"Konidaris Tasos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President & CFO"}}],"security":"Performance-Based Restricted Stock Units","published_at":"2023-03-07T23:00:52.000Z","date":"2023-03-03","kind":"grant","acquired":true,"shares":458716,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock."},{"field":"shares","element":"transactionShares","label":"F6","text":"Represents a performance-based restricted stock unit grant of 229,358 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2026, the last day of the performance period."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Represents a performance-based restricted stock unit grant of 229,358 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2026, the last day of the performance period."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Represents a performance-based restricted stock unit grant of 229,358 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2026, the last day of the performance period."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F6","text":"Represents a performance-based restricted stock unit grant of 229,358 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2026, the last day of the performance period."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"Represents a performance-based restricted stock unit grant of 229,358 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2026, the last day of the performance period."}],"balance_after":458716,"derivative":{"underlying":"Class A Common Stock","underlying_shares":458716},"source":{"system":"sec-edgar","filing":"0001209191-23-016933","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000120919123016933/doc4.xml","form_type":"4"}},{"id":1966088,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":62572,"kind":"person","name":"Konidaris Tasos","position":1,"cik":"0001320982","reported_name":"Konidaris Tasos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President & CFO"}}],"security":"Restricted Stock Units","published_at":"2023-03-07T23:00:52.000Z","date":"2023-03-03","kind":"grant","acquired":true,"shares":229358,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock units vest in four equal annual installments beginning on March 3, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The restricted stock units vest in four equal annual installments beginning on March 3, 2024."}],"balance_after":229358,"derivative":{"underlying":"Class A Common Stock","underlying_shares":229358},"source":{"system":"sec-edgar","filing":"0001209191-23-016933","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000120919123016933/doc4.xml","form_type":"4"}},{"id":1966087,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":62572,"kind":"person","name":"Konidaris Tasos","position":1,"cik":"0001320982","reported_name":"Konidaris Tasos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President & CFO"}}],"security":"Restricted Stock Units","published_at":"2023-03-07T23:00:52.000Z","date":"2023-03-03","kind":"exercise","acquired":false,"shares":45289,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On March 3, 2022, the reporting person was granted 181,159 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On March 3, 2022, the reporting person was granted 181,159 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date."}],"balance_after":135870,"derivative":{"underlying":"Class A Common Stock","underlying_shares":45289},"source":{"system":"sec-edgar","filing":"0001209191-23-016933","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000120919123016933/doc4.xml","form_type":"4"}},{"id":1966086,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":62572,"kind":"person","name":"Konidaris Tasos","position":1,"cik":"0001320982","reported_name":"Konidaris Tasos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President & CFO"}}],"security":"Class A Common Stock","published_at":"2023-03-07T23:00:52.000Z","date":"2023-03-03","kind":"exercise","acquired":true,"shares":45289,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of the Issuer's Class A Common Stock awarded to the reporting person in connection with the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock."}],"balance_after":293121,"source":{"system":"sec-edgar","filing":"0001209191-23-016933","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000120919123016933/doc4.xml","form_type":"4"}},{"id":1973922,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":62572,"kind":"person","name":"Konidaris Tasos","position":1,"cik":"0001320982","reported_name":"Konidaris Tasos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President & CFO"}}],"security":"Restricted Stock Units","published_at":"2023-03-03T21:30:26.000Z","date":"2023-03-01","kind":"exercise","acquired":false,"shares":36197,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On March 1, 2021, the reporting person was granted 144,788 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On March 1, 2021, the reporting person was granted 144,788 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date."}],"balance_after":72394,"derivative":{"underlying":"Class A Common Stock","underlying_shares":36197},"source":{"system":"sec-edgar","filing":"0001209191-23-015516","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000120919123015516/doc4.xml","form_type":"4"}},{"id":1973921,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":62572,"kind":"person","name":"Konidaris Tasos","position":1,"cik":"0001320982","reported_name":"Konidaris Tasos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President & CFO"}}],"security":"Class A Common Stock","published_at":"2023-03-03T21:30:26.000Z","date":"2023-03-01","kind":"exercise","acquired":true,"shares":36197,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of the Issuer's Class A Common Stock awarded to the reporting person in connection with the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock."}],"balance_after":247832,"source":{"system":"sec-edgar","filing":"0001209191-23-015516","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000120919123015516/doc4.xml","form_type":"4"}},{"id":2333374,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":62572,"kind":"person","name":"Konidaris Tasos","position":1,"cik":"0001320982","reported_name":"Konidaris Tasos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President & CFO"}}],"security":"Restricted Stock Units","published_at":"2022-03-15T21:30:17.000Z","date":"2022-03-12","kind":"exercise","acquired":false,"shares":87719,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On March 12, 2020, the reporting person was granted 350,877 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On March 12, 2020, the reporting person was granted 350,877 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date."}],"balance_after":175439,"derivative":{"underlying":"Class A Common Stock","underlying_shares":87719},"source":{"system":"sec-edgar","filing":"0001209191-22-018891","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000120919122018891/doc4.xml","form_type":"4"}},{"id":2333373,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":62572,"kind":"person","name":"Konidaris Tasos","position":1,"cik":"0001320982","reported_name":"Konidaris Tasos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President & CFO"}}],"security":"Class A Common Stock","published_at":"2022-03-15T21:30:17.000Z","date":"2022-03-12","kind":"exercise","acquired":true,"shares":87719,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares of the Issuer's Class A Common Stock awarded to the reporting person in connection with the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock."}],"balance_after":211635,"source":{"system":"sec-edgar","filing":"0001209191-22-018891","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000120919122018891/doc4.xml","form_type":"4"}},{"id":2354821,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":62572,"kind":"person","name":"Konidaris Tasos","position":1,"cik":"0001320982","reported_name":"Konidaris Tasos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President & CFO"}}],"security":"Performance-Based Restricted Stock Units","published_at":"2022-03-04T02:19:26.000Z","date":"2022-03-03","kind":"grant","acquired":true,"shares":362318,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock."},{"field":"shares","element":"transactionShares","label":"F6","text":"Represents a performance-based restricted stock unit grant of 181,159 target shares.  The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. The number of performance-based restricted stock units reported represents the maximum number of shares issuable under the award.  The number that would be received upon vesting, if any, may vary from 0% to 200% of the target number.  The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award.  Any earned performance-based restricted stock units vest in full on February 28, 2025, the last day of the performance period."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Represents a performance-based restricted stock unit grant of 181,159 target shares.  The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. The number of performance-based restricted stock units reported represents the maximum number of shares issuable under the award.  The number that would be received upon vesting, if any, may vary from 0% to 200% of the target number.  The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award.  Any earned performance-based restricted stock units vest in full on February 28, 2025, the last day of the performance period."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Represents a performance-based restricted stock unit grant of 181,159 target shares.  The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. The number of performance-based restricted stock units reported represents the maximum number of shares issuable under the award.  The number that would be received upon vesting, if any, may vary from 0% to 200% of the target number.  The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award.  Any earned performance-based restricted stock units vest in full on February 28, 2025, the last day of the performance period."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F6","text":"Represents a performance-based restricted stock unit grant of 181,159 target shares.  The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. The number of performance-based restricted stock units reported represents the maximum number of shares issuable under the award.  The number that would be received upon vesting, if any, may vary from 0% to 200% of the target number.  The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award.  Any earned performance-based restricted stock units vest in full on February 28, 2025, the last day of the performance period."}],"balance_after":362318,"derivative":{"underlying":"Class A Common Stock","underlying_shares":362318},"source":{"system":"sec-edgar","filing":"0001209191-22-016050","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000120919122016050/doc4.xml","form_type":"4"}},{"id":2354820,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":62572,"kind":"person","name":"Konidaris Tasos","position":1,"cik":"0001320982","reported_name":"Konidaris Tasos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President & CFO"}}],"security":"Restricted Stock Units","published_at":"2022-03-04T02:19:26.000Z","date":"2022-03-03","kind":"grant","acquired":true,"shares":181159,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock units vest in four equal annual installments beginning on March 3, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The restricted stock units vest in four equal annual installments beginning on March 3, 2023."}],"balance_after":181159,"derivative":{"underlying":"Class A Common Stock","underlying_shares":181159},"source":{"system":"sec-edgar","filing":"0001209191-22-016050","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000120919122016050/doc4.xml","form_type":"4"}},{"id":2354819,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":62572,"kind":"person","name":"Konidaris Tasos","position":1,"cik":"0001320982","reported_name":"Konidaris Tasos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President & CFO"}}],"security":"Restricted Stock Units","published_at":"2022-03-04T02:19:26.000Z","date":"2022-03-01","kind":"exercise","acquired":false,"shares":36197,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On March 1, 2021, the reporting person was granted 144,788 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On March 1, 2021, the reporting person was granted 144,788 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date."}],"balance_after":108591,"derivative":{"underlying":"Class A Common Stock","underlying_shares":36197},"source":{"system":"sec-edgar","filing":"0001209191-22-016050","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000120919122016050/doc4.xml","form_type":"4"}},{"id":2354818,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":62572,"kind":"person","name":"Konidaris Tasos","position":1,"cik":"0001320982","reported_name":"Konidaris Tasos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President & CFO"}}],"security":"Class A Common Stock","published_at":"2022-03-04T02:19:26.000Z","date":"2022-03-01","kind":"exercise","acquired":true,"shares":36197,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of the Issuer's Class A Common Stock awarded to the reporting person in connection with the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock."}],"balance_after":123916,"source":{"system":"sec-edgar","filing":"0001209191-22-016050","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000120919122016050/doc4.xml","form_type":"4"}},{"id":2519352,"issuer":{"id":133686,"kind":"organization","name":"Kadmon Holdings, Inc.","symbol":"KDMN"},"owners":[{"id":62572,"kind":"person","name":"Konidaris Tasos","position":1,"cik":"0001320982","reported_name":"Konidaris Tasos","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-11-09T17:36:52.000Z","date":"2021-11-09","kind":"disposition_to_issuer","acquired":false,"shares":116370,"price":5.92,"value":688910.4,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the payment per share of Common Stock received in exchange for the cancellation of each Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"In connection with the acquisition by Sanofi of the entire issued share capital of Issuer on November 9, 2021 by means of a plan of merger, all unvested stock options (\"Options\") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option."}],"balance_after":0,"derivative":{"exercise_price":3.58,"expiration_date":"2031-05-12","underlying":"Common Stock, par value $0.001","underlying_shares":116370},"source":{"system":"sec-edgar","filing":"0001104659-21-136399","document":"tm2131118-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1320982/000110465921136399/tm2131118-3_4seq1.xml","form_type":"4"}},{"id":2519351,"issuer":{"id":133686,"kind":"organization","name":"Kadmon Holdings, Inc.","symbol":"KDMN"},"owners":[{"id":62572,"kind":"person","name":"Konidaris Tasos","position":1,"cik":"0001320982","reported_name":"Konidaris Tasos","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-11-09T17:36:52.000Z","date":"2021-11-09","kind":"disposition_to_issuer","acquired":false,"shares":102040,"price":5.06,"value":516322.4,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the payment per share of Common Stock received in exchange for the cancellation of each Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"In connection with the acquisition by Sanofi of the entire issued share capital of Issuer on November 9, 2021 by means of a plan of merger, all unvested stock options (\"Options\") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option."}],"balance_after":0,"derivative":{"exercise_price":4.44,"expiration_date":"2030-05-13","underlying":"Common Stock, par value $0.001","underlying_shares":102040},"source":{"system":"sec-edgar","filing":"0001104659-21-136399","document":"tm2131118-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1320982/000110465921136399/tm2131118-3_4seq1.xml","form_type":"4"}},{"id":2519350,"issuer":{"id":133686,"kind":"organization","name":"Kadmon Holdings, Inc.","symbol":"KDMN"},"owners":[{"id":62572,"kind":"person","name":"Konidaris Tasos","position":1,"cik":"0001320982","reported_name":"Konidaris Tasos","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-11-09T17:36:52.000Z","date":"2021-11-09","kind":"disposition_to_issuer","acquired":false,"shares":100000,"price":7.21,"value":721000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the payment per share of Common Stock received in exchange for the cancellation of each Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"In connection with the acquisition by Sanofi of the entire issued share capital of Issuer on November 9, 2021 by means of a plan of merger, all unvested stock options (\"Options\") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option."}],"balance_after":0,"derivative":{"exercise_price":2.29,"expiration_date":"2029-05-15","underlying":"Common Stock, par value $0.001","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001104659-21-136399","document":"tm2131118-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1320982/000110465921136399/tm2131118-3_4seq1.xml","form_type":"4"}},{"id":2519349,"issuer":{"id":133686,"kind":"organization","name":"Kadmon Holdings, Inc.","symbol":"KDMN"},"owners":[{"id":62572,"kind":"person","name":"Konidaris Tasos","position":1,"cik":"0001320982","reported_name":"Konidaris Tasos","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-11-09T17:36:52.000Z","date":"2021-11-09","kind":"disposition_to_issuer","acquired":false,"shares":50000,"price":6.15,"value":307500.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the payment per share of Common Stock received in exchange for the cancellation of each Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"In connection with the acquisition by Sanofi of the entire issued share capital of Issuer on November 9, 2021 by means of a plan of merger, all unvested stock options (\"Options\") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option."}],"balance_after":0,"derivative":{"exercise_price":3.35,"expiration_date":"2028-07-27","underlying":"Common Stock, par value $0.001","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001104659-21-136399","document":"tm2131118-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1320982/000110465921136399/tm2131118-3_4seq1.xml","form_type":"4"}},{"id":2519348,"issuer":{"id":133686,"kind":"organization","name":"Kadmon Holdings, Inc.","symbol":"KDMN"},"owners":[{"id":62572,"kind":"person","name":"Konidaris Tasos","position":1,"cik":"0001320982","reported_name":"Konidaris Tasos","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-11-09T17:36:52.000Z","date":"2021-11-09","kind":"disposition_to_issuer","acquired":false,"shares":50000,"price":5.38,"value":269000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the payment per share of Common Stock received in exchange for the cancellation of each Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"In connection with the acquisition by Sanofi of the entire issued share capital of Issuer on November 9, 2021 by means of a plan of merger, all unvested stock options (\"Options\") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option."}],"balance_after":0,"derivative":{"exercise_price":4.12,"expiration_date":"2027-06-29","underlying":"Common Stock, par value $0.001","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001104659-21-136399","document":"tm2131118-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1320982/000110465921136399/tm2131118-3_4seq1.xml","form_type":"4"}},{"id":2714151,"issuer":{"id":133686,"kind":"organization","name":"Kadmon Holdings, Inc.","symbol":"KDMN"},"owners":[{"id":62572,"kind":"person","name":"Konidaris Tasos","position":1,"cik":"0001320982","reported_name":"Konidaris Tasos","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-05-13T16:04:09.000Z","date":"2021-05-12","kind":"grant","acquired":true,"shares":116370,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in full on the first anniversary of the grant date, or May 12, 2022"}],"balance_after":116370,"derivative":{"exercise_price":3.58,"expiration_date":"2031-05-12","underlying":"Common stock","underlying_shares":116370},"source":{"system":"sec-edgar","filing":"0001593968-21-001309","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1320982/000159396821001309/primary_01.xml","form_type":"4"}},{"id":2789292,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":62572,"kind":"person","name":"Konidaris Tasos","position":1,"cik":"0001320982","reported_name":"Konidaris Tasos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President & CFO"}}],"security":"Restricted Stock Units","published_at":"2021-03-15T20:06:22.000Z","date":"2021-03-12","kind":"exercise","acquired":false,"shares":87719,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On March 12,2020, the reporting person was granted 350,877 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On March 12,2020, the reporting person was granted 350,877 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date."}],"balance_after":263158,"derivative":{"underlying":"Class A Common Stock","underlying_shares":87719},"source":{"system":"sec-edgar","filing":"0001209191-21-020434","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000120919121020434/doc4.xml","form_type":"4"}},{"id":2789291,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":62572,"kind":"person","name":"Konidaris Tasos","position":1,"cik":"0001320982","reported_name":"Konidaris Tasos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President & CFO"}}],"security":"Class A Common Stock","published_at":"2021-03-15T20:06:22.000Z","date":"2021-03-12","kind":"exercise","acquired":true,"shares":87719,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock."}],"balance_after":87719,"source":{"system":"sec-edgar","filing":"0001209191-21-020434","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000120919121020434/doc4.xml","form_type":"4"}},{"id":2814134,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":62572,"kind":"person","name":"Konidaris Tasos","position":1,"cik":"0001320982","reported_name":"Konidaris Tasos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President & CFO"}}],"security":"Performance-Based Restricted Stock Units","published_at":"2021-03-03T22:03:28.000Z","date":"2021-03-01","kind":"grant","acquired":true,"shares":289576,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock."},{"field":"shares","element":"transactionShares","label":"F4","text":"Represents the maximum number of shares issuable under the performance-based restricted stock units."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"50% of the performance-based restricted stock units are earned and eligible to vest upon the Issuer's Class A Common Stock achieving an average closing price per share of $8 or higher for 60 consecutive calendar days during the three-year performance period. Additional performance-based restricted stock units are earned at higher levels and eligible to vest upon the Issuer's Class A Common Stock achieving an average closing price per share of $10 (75%), $12 (100%), $14 (125%), $16 (150%), $18 (175%) and $20 (200%), respectively, for 60 consecutive calendar days during the three-year performance period. For average 60-day closing stock prices between $12 and $20 per share, the number of performance-based restricted stock units that become earned will be determined using straight line interpolation. Any earned performance-based restricted stock units vest in full on February 29,2024, the last day of the performance period."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"50% of the performance-based restricted stock units are earned and eligible to vest upon the Issuer's Class A Common Stock achieving an average closing price per share of $8 or higher for 60 consecutive calendar days during the three-year performance period. Additional performance-based restricted stock units are earned at higher levels and eligible to vest upon the Issuer's Class A Common Stock achieving an average closing price per share of $10 (75%), $12 (100%), $14 (125%), $16 (150%), $18 (175%) and $20 (200%), respectively, for 60 consecutive calendar days during the three-year performance period. For average 60-day closing stock prices between $12 and $20 per share, the number of performance-based restricted stock units that become earned will be determined using straight line interpolation. Any earned performance-based restricted stock units vest in full on February 29,2024, the last day of the performance period."}],"balance_after":289576,"derivative":{"underlying":"Class A Common Stock","underlying_shares":289576},"source":{"system":"sec-edgar","filing":"0001209191-21-016983","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000120919121016983/doc4.xml","form_type":"4"}},{"id":2814133,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":62572,"kind":"person","name":"Konidaris Tasos","position":1,"cik":"0001320982","reported_name":"Konidaris Tasos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President & CFO"}}],"security":"Restricted Stock Units","published_at":"2021-03-03T22:03:28.000Z","date":"2021-03-01","kind":"grant","acquired":true,"shares":144788,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units vest in four equal annual installments beginning on March 1, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units vest in four equal annual installments beginning on March 1, 2022."}],"balance_after":144788,"derivative":{"underlying":"Class A Common Stock","underlying_shares":144788},"source":{"system":"sec-edgar","filing":"0001209191-21-016983","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000120919121016983/doc4.xml","form_type":"4"}},{"id":3148596,"issuer":{"id":133686,"kind":"organization","name":"Kadmon Holdings, Inc.","symbol":"KDMN"},"owners":[{"id":62572,"kind":"person","name":"Konidaris Tasos","position":1,"cik":"0001320982","reported_name":"Konidaris Tasos","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-05-14T16:28:42.000Z","date":"2020-05-13","kind":"grant","acquired":true,"shares":102040,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option becomes vested and exercisable on May 13, 2021."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Only represents derivative securities of this class."}],"balance_after":102040,"derivative":{"exercise_price":4.44,"exercise_date":"2021-05-13","expiration_date":"2030-05-13","underlying":"Common stock, $0.001 par value","underlying_shares":102040},"source":{"system":"sec-edgar","filing":"0001593968-20-001176","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1320982/000159396820001176/primary_01.xml","form_type":"4"}},{"id":3209025,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":62572,"kind":"person","name":"Konidaris Tasos","position":1,"cik":"0001320982","reported_name":"Konidaris Tasos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and CFO"}}],"security":"Performance-Based Restricted Stock Units","published_at":"2020-03-16T20:02:22.000Z","date":"2020-03-12","kind":"grant","acquired":true,"shares":701754,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock."},{"field":"shares","element":"transactionShares","label":"F4","text":"Represents the maximum number of shares issuable under the performance-based restricted stock units."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"25% of the performance-based restricted stock units are earned and eligible to vest upon the Issuer's Class A Common Stock achieving an average closing price per share of $8 or higher for 60 consecutive calendar days during the three-year performance period. An additional 12.5% of the performance-based restricted stock units are earned and eligible to vest upon the Issuer's Class A Common Stock achieving an average closing price per share of $10, $12, $14, $16, $18 and $20, respectively, for 60 consecutive calendar days during the three-year performance period. For average 60-day closing stock prices between $12 and $20 per share, the number of performance-based restricted stock units that become earned will be determined using straight line interpolation. Any earned performance-based restricted stock units vest in full on February 28, 2023, the last day of the performance period."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"25% of the performance-based restricted stock units are earned and eligible to vest upon the Issuer's Class A Common Stock achieving an average closing price per share of $8 or higher for 60 consecutive calendar days during the three-year performance period. An additional 12.5% of the performance-based restricted stock units are earned and eligible to vest upon the Issuer's Class A Common Stock achieving an average closing price per share of $10, $12, $14, $16, $18 and $20, respectively, for 60 consecutive calendar days during the three-year performance period. For average 60-day closing stock prices between $12 and $20 per share, the number of performance-based restricted stock units that become earned will be determined using straight line interpolation. Any earned performance-based restricted stock units vest in full on February 28, 2023, the last day of the performance period."}],"balance_after":701754,"derivative":{"underlying":"Class A Common Stock","underlying_shares":701754},"source":{"system":"sec-edgar","filing":"0000899243-20-008429","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000089924320008429/doc4.xml","form_type":"4"}},{"id":3209024,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":62572,"kind":"person","name":"Konidaris Tasos","position":1,"cik":"0001320982","reported_name":"Konidaris Tasos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and CFO"}}],"security":"Restricted Stock Units","published_at":"2020-03-16T20:02:22.000Z","date":"2020-03-12","kind":"grant","acquired":true,"shares":350877,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units vest in four equal annual installments beginning on March 12, 2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units vest in four equal annual installments beginning on March 12, 2021."}],"balance_after":350877,"derivative":{"underlying":"Class A Common Stock","underlying_shares":350877},"source":{"system":"sec-edgar","filing":"0000899243-20-008429","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000089924320008429/doc4.xml","form_type":"4"}},{"id":3523302,"issuer":{"id":133686,"kind":"organization","name":"Kadmon Holdings, Inc.","symbol":"KDMN"},"owners":[{"id":62572,"kind":"person","name":"Konidaris Tasos","position":1,"cik":"0001320982","reported_name":"Konidaris Tasos","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-05-16T16:52:32.000Z","date":"2019-05-15","kind":"grant","acquired":true,"shares":100000,"price":2.29,"value":229000.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option becomes vested and exercisable on May 15, 2020."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Only represents derivative securities of this class."}],"balance_after":200000,"derivative":{"exercise_price":2.29,"exercise_date":"2020-05-15","expiration_date":"2029-05-15","underlying":"Common stock, par value $0.001","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001593968-19-001125","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1320982/000159396819001125/primary_01.xml","form_type":"4"}},{"id":3858912,"issuer":{"id":133686,"kind":"organization","name":"Kadmon Holdings, Inc.","symbol":"KDMN"},"owners":[{"id":62572,"kind":"person","name":"Konidaris Tasos","position":1,"cik":"0001320982","reported_name":"Konidaris Tasos","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-07-30T17:10:39.000Z","date":"2018-07-27","kind":"grant","acquired":true,"shares":50000,"price":3.35,"value":167500.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option becomes vested and exercisable on July 27, 2018."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Only represents derivative securities of this class."}],"balance_after":100000,"derivative":{"exercise_price":3.35,"expiration_date":"2028-07-27","underlying":"Common Stock, par value $0.001","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001593968-18-001079","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1320982/000159396818001079/primary_01.xml","form_type":"4"}},{"id":4269015,"issuer":{"id":133686,"kind":"organization","name":"Kadmon Holdings, Inc.","symbol":"KDMN"},"owners":[{"id":62572,"kind":"person","name":"Konidaris Tasos","position":1,"cik":"0001320982","reported_name":"Konidaris Tasos","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-06-30T18:49:11.000Z","date":"2017-06-29","kind":"grant","acquired":true,"shares":50000,"price":4.12,"value":206000.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option becomes vested and exercisable on June 29, 2018."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Only represents derivative securities of this class."}],"balance_after":50000,"derivative":{"exercise_price":4.12,"expiration_date":"2027-06-29","underlying":"Common Stock, par value $0.001","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001593968-17-000845","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1320982/000159396817000845/primary_01.xml","form_type":"4"}}]}